The Charité – Universitätsmedizin Berlin is one of Europe's largest university hospitals, affiliated with Humboldt University and Free University Berlin. With numerous Collaborative Research Centres of the German Research Foundation it is one of Germany's most research-intensive medical institutions.

During the past decade, Dept. of Hematology/Oncology, Charité Berlin conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dept. of Hematology/Oncology, Charité Berlin" #1 collaborator was "Aventis Pharmaceuticals" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator, "Pierre Fabre Pharma GmbH" with 1 trials as a collaborator and "ribosepharm GmbH" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Dept. of Hematology/Oncology, Charité Berlin" are "Chronic Myeloid Leukemia" (2 trials), "Multiple Myeloma" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Ocular Melanoma" (1 trials) and "Recurrent Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Dept. of Hematology/Oncology, Charité Berlin" in a lesser frequency.

Most popular intervention types in "Dept. of Hematology/Oncology, Charité Berlin" are "Drug" (6 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bendamustin/Ribomustin" (1 trials), "Carboplatin" (1 trials), "Carboplatin plus Irinotecan vs Carboplatin plus Etoposide" (1 trials), "Gemcitabine" (1 trials) and "Imatinib mesylate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dept. of Hematology/Oncology, Charité Berlin" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Dept. of Hematology/Oncology, Charité Berlin". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Dept. of Hematology/Oncology, Charité Berlin, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dept. of Hematology/Oncology, Charité Berlin, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".